Dr. Nikiforov on Reclassifying Subtype of Thyroid Cancer

Yuri E. Nikiforov, MD, PhD
Published: Thursday, Mar 02, 2017



Yuri E. Nikiforov, MD, PhD, professor of Pathology, vice chair of the Department of Pathology, director, Division of Molecular & Genomic Pathology, University of Pittsburgh, discusses research that demonstrated the need to reclassify a subtype of thyroid cancer as not cancerous.

Some subtypes of thyroid cancer are indolent while others are very aggressive, Nikiforov explains. However, a certain type of thyroid cancer is very indolent and rarely causes harm to patients. While conducting long-term folllow-up of this specific patient population, research concluded that most of the patients lived a normal live and did not experience any adverse outcomes associated with the disease.

Therefore, the name is suggested to be reclassified as noninvasive follicular tumors, also known as a noninvasive follicular thyroid neoplasm with papillary-like nuclear features. They will no longer be labeled with the term cancer, he adds.


Yuri E. Nikiforov, MD, PhD, professor of Pathology, vice chair of the Department of Pathology, director, Division of Molecular & Genomic Pathology, University of Pittsburgh, discusses research that demonstrated the need to reclassify a subtype of thyroid cancer as not cancerous.

Some subtypes of thyroid cancer are indolent while others are very aggressive, Nikiforov explains. However, a certain type of thyroid cancer is very indolent and rarely causes harm to patients. While conducting long-term folllow-up of this specific patient population, research concluded that most of the patients lived a normal live and did not experience any adverse outcomes associated with the disease.

Therefore, the name is suggested to be reclassified as noninvasive follicular tumors, also known as a noninvasive follicular thyroid neoplasm with papillary-like nuclear features. They will no longer be labeled with the term cancer, he adds.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder CancersApr 28, 20182.0
Publication Bottom Border
Border Publication
x